glp-1 drugs microdosing Medications GLP-1 Microdosing vs. Standard Dosing:

however, their use is limited due to the development of intolerable anticholinergic adverse events, including confusion, drowsiness, memory impairment, dry mouth, constipation, and visual changes

Compared with nonusers, adults taking GLP-1s had a: 17 percent lower risk of venous thromboembolism, or blood clots in the veins 31 percent lower risk of pulmonary embolism, a potentially life-threatening clot that travels to the lungs 21 percent lower risk of going to the emergency department 44 percent lower risk of all-cause mortality (death from any cause) Researchers also observed lower stroke rates among GLP-1 users, although this difference didnt reach statistical significance

Market cap gains far exceed historical trends: In an equivalent time period prior to the launch of their GLP-1 products, the combined market cap gains for Novo Nordisk and Eli Lilly was significantly lower at $197 billion3.5x less than the gains realized after the introduction of these products

While Roundhill GLP-1 & Weight Loss ETF currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys

Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, et al

Neurotherapeutics 18 (2), 962978